Proteomic Biomarkers of Severity and Outcomes in Interstitial Lung Abnormalities
J.A. Rose(Brigham and Women's Hospital), Gary M. Hunninghake(Hubei University of Science and Technology), David A. Lynch(McMaster University), A.-M.C. Tukpah(Brigham and Women's Hospital), Iván O. Rosas(Brigham and Women's Hospital), G.R. Washko(Brigham and Women's Hospital), Rachel K. Putman(Brigham and Women's Hospital), Benjamin A. Raby(Brigham and Women's Hospital), Hiroto Hatabu(Harvard University), Mizuki Nishino(Brigham and Women's Hospital), Claire C. Cutting(Brigham and Women's Hospital), Matthew Moll(Brigham and Women's Hospital), S. Kalra(Brigham and Women's Hospital), M.H. Cho(Brigham and Women's Hospital), Edward Silverman(Brigham and Women's Hospital), Russell P. Bowler(Cleveland Clinic)
American Journal of Respiratory and Critical Care Medicine
May 1, 2025
Cited by 0
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Genetic Epidemiology of COPD (COPDGene) Study Design
|COPD Journal of Chronic Obstructive Pulmonary Disease|2010|1.3k
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2012|1.3k
Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
|JAMA Oncology|2016|750
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2011|713